Country for PR: United Kingdom
Contributor: PR Newswire Europe
Saturday, August 15 2020 - 23:05
AsiaNet
Sai Life Sciences Opens New, State-of-the-Art Research & Technology Centre in Hyderabad
HYDERABAD, India, August 15, 2020 /PRNewswire-AsiaNet/ --

- Completes first phase in committed investment of US$ 150M (> INR 1000 Cr)
 
- Sri KT Rama Rao, Hon’ble Minister for Industry & Commerce and IT, Government 
  of Telangana inaugurates the facility

Sai Life Sciences, one of India’s fastest growing Contract Development & 
Manufacturing Organizations (CDMOs), [ 
https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=resandtechcentre] 
today announced the inauguration of its new Research and Technology (R&T) 
Centre in Hyderabad, India. Sri K T Rama Rao, Hon’ble Minister for Industry & 
Commerce and IT, Government of Telangana formally inaugurated the facility in 
the presence of other dignitaries. 

Speaking on the occasion, Sri KT Rama Rao said, “I’m very happy that the 
esteemed leadership of Sai Life sciences has considered Telangana for setting 
up their new R&D centre. Life Sciences is one of the key focus sectors for the 
Government of Telangana. Hyderabad serves more than 1000 global innovators in 
their vision to develop innovative and affordable medicines for the world. I 
sincerely congratulate the entire team of Sai Life Sciences, not only for the 
new Research & Technology Centre but, also for their work towards the 
development and manufacturing of new life saving medicines.”

Built with an aspiration to achieve the best global benchmarks in lab 
infrastructure, the new R&T facility [ 
https://www.sailife.com/research-technology-centre-hyderabad/?utm_source=pr&utm_medium=web&utm_campaign=resandtechcentre] 
has several unique aspects such as intelligent & ergonomic lab design to 
enhance safety and productivity, advanced automation for seamless data capture 
during process development, lean & 5S approach to enhance productivity and 
collaborative workspaces for engendering innovation. 

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life 
Sciences said, “Our philosophy behind building this new facility was to go 
beyond what the norm is in India and to create what our global innovator 
partners expect in their inhouse capabilities.” He further added, “We are an 
example of what is possible in Hyderabad’s rich life sciences ecosystem. Today, 
as we build world class R&D capabilities and invest in nurturing talent with 
deep domain expertise, I can unhesitatingly say, Hyderabad is truly a city 
where pharma dreams are made.”

The new 83,000 sq.ft. (7700 sq.m.) facility houses state-of-the-art research 
capabilities and advanced technology platforms, augmenting the company’s 
capabilities in providing superior scientific solutions to its pharma and 
biotech innovator customers globally. It has 24 chemistry labs with 250 fume 
hoods, analytical labs, fully equipped technology suite and a dedicated process 
safety lab. 

Sai Life Sciences began a process of organizational transformation in 2019 
reinventing itself as a new generation global CDMO. Through this initiative, 
named Sai Nxt, the company is investing over US$ 150M (> INR 1000 Cr) to expand 
and upgrade its R&D and manufacturing facilities, induct top-notch global 
scientific and leadership talent, strengthen automation and data systems, and 
above all raise the bar for safety, quality and customer focus.
 
About Sai Life Sciences

Sai Life Sciences is a full-service CDMO driven by a vision to support the 
launch of 25 new medicines by 2025.  It works with innovator pharma and biotech 
companies globally, accelerating the discovery, development and manufacture of 
complex small molecules. A pure-play CDMO, Sai Life Sciences has served a 
diverse set of NCE development programs, consistently delivering value based on 
its quality and responsiveness. Today, it works with 7 of the top 10 large 
pharma companies, as well as several small and mid-sized pharma & biotech 
companies. Sai Life Sciences is privately held and backed by global investors, 
TPG Capital and HBM Healthcare Investments. https://www.sailife.com/

Photo - https://mma.prnewswire.com/media/1228693/Sai_Life_Sciences.jpg
Photo - https://mma.prnewswire.com/media/1228696/Sci_Life_Sciences_Centre.jpg
Logo - https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

Source : Sai Life Sciences
Translations

Japanese